Table 3.
Efficacy of a single dose of gamithromycin in preventing bovine respiratory disease (BRD), shown as the number and proportion of treatment successes and the percentage morbidity, assessed 14 days after treatment
| Gamithromycin* | Control† | |||||
|---|---|---|---|---|---|---|
| Trial site | Number (%) of treatment successes | Morbidity‡ (%) | Number (%) of treatment successes | Morbidity (%) | Morbidity reduction (%) | P |
| France | 34/42 (81) | 19 | 31/43 (72) | 28 | 32 | 0.4444§ |
| Germany 1 | 41/60 (68) | 32 | 17/60 (28) | 72 | 56 | <0.0001§ |
| Germany 2 | 46/61 (75) | 25 | 23/63 (37) | 63 | 60 | <0.0001§ |
| Italy 1 | 113/121 (93) | 7 | 90/121 (74) | 26 | 73 | <0.0001§ |
| Italy 2 | 107/113 (95) | 5 | 82/114 (72) | 28 | 82 | <0.0001§ |
| Total | 341/397 (86) | 14 | 243/401 (61) | 39 | 64 | 0.0012∞ |
Gamithromycin 150 mg/ml injectable solution at 6 mg/kg (2 ml/50 kg) bodyweight
Sterile 0.9 per cent saline solution at 2 ml/50 kg bodyweight
Morbidity is the percentage of BRD cases in the control or gamithromycin-treated groups. Morbidity reduction is the ratio of morbidity in gamithromycin-treated cattle to controls
Probability from Fisher's exact test for the proportion of treatment success in the individual trial site in gamithromycin-treated versus saline-treated control groups
Probability from generalised linear model analysis for the proportion of treatment success in the combined gamithromycin-treated versus saline-treated control groups